European Brachytherapy Market Size to Reach $436.7 Million by 2035

European brachytherapy market size reached $315.6 million in 2025 and is projected to expand to $436.7 million by 2035, growing at a CAGR of 3.3% during the forecast period (2026–2035). Market growth is supported by increasing cancer incidence, expansion of radiotherapy infrastructure, and wider adoption of minimally invasive treatment techniques.

KEY MARKET DRIVERS

• Rising prevalence of prostate, breast, and gynecological cancers across aging populations
• Increased hospital investments in radiation oncology and specialized cancer centers
• Growing preference for localized radiation therapies with reduced systemic exposure
• Expanding clinical guidelines supporting brachytherapy in early-stage cancers
• Technological improvements in imaging and treatment planning systems

Browse the full report description of “European Brachytherapy Market Size, Share & Trends Analysis Report by Indication (Breast Cancer, Gynecological Cancer, Prostate Cancer, Skin Cancer, Brain Cancer, and Others), and by Type (Low-Dose Rate (LDR) Brachytherapy and High-Dose Rate (HDR) Brachytherapy), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/europe-brachytherapy-market

REGIONAL ANALYSIS

Europe represents the entire scope of the regional market, characterized by structured public healthcare systems and consistent investments in oncology care. Several European countries allocate significant portions of healthcare budgets to cancer treatment under national cancer control plans. In Germany, France, and the United Kingdom, government-funded screening programs contribute to early diagnosis, increasing demand for targeted radiotherapy procedures such as brachytherapy. The European Society for Radiotherapy and Oncology (ESTRO) continues to promote standardized training and treatment protocols, supporting clinical adoption across hospitals. Additionally, reimbursement frameworks under national health services facilitate access to brachytherapy procedures, particularly for prostate and breast cancer indications, where localized treatment outcomes are well documented.

COMPETITIVE LANDSCAPE

Key companies operating in the European brachytherapy market include Elekta, Varian Medical Systems, Eckert & Ziegler, iCAD, BEV Radiology, Theragenics, IsoAid, and CIVCO Medical Solutions.

These companies operate across system manufacturing, radioactive source supply, treatment planning software, and procedural accessories. Market participation is structured around regulatory compliance with European Medicines Agency and national radiation safety authorities. Strategic focus remains on product reliability, treatment accuracy, and hospital integration rather than volume-based expansion.

RECENT MARKET DEVELOPMENTS

• In May 2024, GT Medical Technologies and Theragenics announced a strategic distribution partnership for Cesium-131 seeds. The development supports expanded physician access to brachytherapy materials for prostate and brain cancer treatments.
• In April 2024, Maastro, in collaboration with Varian, developed a partially 3D-printed brachytherapy applicator for rectal cancer. The development supports improved HDR brachytherapy delivery by enabling precise tumor targeting while reducing quality-of-life risks associated with surgical intervention.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Indication 
  • By Type
• Competitive Landscape - Becton, Dickinson and Company (BD), Carl Zeiss Meditec AG, Elekta AB, Eckert & Ziegler BEBIG, Varian Medical Systems, among others. 

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

European Brachytherapy Market Report by Segment

By Indication

• Breast Cancer
• Gynecological Cancer
• Prostate Cancer
• Skin Cancer
• Brain Cancer
• Others

 By Type

• Low-Dose Rate (LDR) Brachytherapy
• High-Dose Rate (HDR) Brachytherapy
• Others

European Brachytherapy Market Report Segment by Region

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/europe-brachytherapy-market